The pharmaceutical industry has long faced Eroom’s Law, which observes that drug development costs roughly double every nine years. Today, bringing a single therapy to market can take more than a decade, cost around $2 billion, and still have only about a 10% success rate. This makes drug development expensive, slow, and risky for investors. Artificial intelligence (AI) is beginning to change this. By integrating computational models into traditional labs, AI is enabling a faster, more efficient approach to drug discovery, marking an important shift for companies and investors alike. One of the most significant ways AI is streamlining drug development is by shifting parts of the design-build-test-learn (DBTL) cycle into a computational "dry lab." Machine learning models can analyze biological data, predict protein structures, and assess whether the target can be effectively drugged. This allows researchers to test ideas digitally before running costly experiments, saving time and resources early in development.
Beyond early-stage discovery, the most significant economic impact of AI lies in reducing clinical failure rates, particularly during Phase II trials. Predictive algorithms can identify potential toxicity or efficacy issues before human testing begins, minimizing risk and improving returns on research expenditures.
AI is also expanding the number and quality of drug candidates entering development. Instead of manually isolating viable candidates through a slow, resource-intensive process, generative AI and structural prediction models can propose millions of optimized sequences, ranking them by binding affinity, specificity, and developability. This automated triage ensures that only the strongest candidates move forward to physical testing, building larger, higher-quality pipelines.
As drug development becomes more efficient, these gains may be reinvested in additional research and trials; this is an economic concept known as the Jevons paradox, where increased efficiency leads to increased overall activity. The efficiency gains will encourage companies to reinvest in additional research, leading to significant advancements across the entire life sciences sector.
AI will not replace the need for physical validation. Regulatory bodies will continue to require empirical evidence of safety and efficacy. However, computational models are enhancing decision-making and accelerating development timelines, making the overall process more efficient.
For investors, this shift presents a compelling opportunity. Companies that leverage AI for target selection and lead optimization are gaining a competitive advantage through faster timelines and lower attrition rates. Investors should keep an eye on pharmaceutical and biotech firms adopting AI technologies, as well as the tools enabling this innovation in drug development.
For more information on related investment opportunities and insights, read From Code to Clinic: How AI Is (and Isn’t) Rewriting the Life of a Drug, published on March 30, 2026, by William Blair healthcare analyst Matt Larew.